Announcement PDF ASX Announcement 16th May 2024 Significant funding commited to HIV Self-Tes�ng in the Federal Budget SYDNEY Australia, 16th May 2024 – Atomo Diagnos�cs Limited (ASX:AT1) (Atomo) welcomes the Australian Federal government’s commitment to fund expansion of HIV Self-Tes�ng in the Budget. • People with or at risk of HIV will receive unprecedented support ($43.9 million) through better prevention, testing, workforce training and information, with the Government committed to eliminating HIV transmission by 2030. • More people in at-risk groups will get free HIV self-test kits through the expanded national HIV self-test mail-out program. • People around Australia will get wider access to HIV testing by extending the South Australia-based HIV testing vending machine pilot to every state and territory. https://www.health.gov.au/sites/default/files/2024-05/budget-2024-25-ensuringall-australians-get-the-health-care-they-need.pdf Atomo supplies the only HIV Self-Test included on the Australian Register of Therapeu�c Goods (ARTG) and has been instrumental in the implementa�on of these pilot programs, now being scaled na�onally through funding support from the Federal Government. Atomo an�cipates that a significant por�on of the funding commited to these expanded HIV SelfTest programs will be used for procurement of Atomo HIV tests. The funding of expanded HIV self-test access in the budget comes a�er the Australian Government’s HIV Taskforce, in November last year, recognised for the first �me the cri�cal role HIV self-tes�ng plays in enabling Australia to reach it HIV targets. Atomo remains commited to con�nuing to work Government and other stakeholders to ensure access to quality HIV self-tests is not a barrier to Australia reaching its 2030 goals. Atomo CEO John Kelly said: “We are delighted to see the government recognise the cri�cal need to ensure HIV Self-Test availability across the community and fund the rapid expansion of the national HIV self-test mail-out program and the HIV self-test vending machine pilots. Both have proven extremely successful in increasing tes�ng rates among groups not currently tes�ng via healthcare facility-based services.” Atomo Diagnostics Limited ACN 142 925 684 Level 1, 3-5 George St Leichhardt NSW 2040 For more information, please contact: John Kelly Atomo Diagnostics john.kelly@atomodiagnostics.com Phone: +61 401 922 279 This announcement was authorised by the Managing Director & CEO. About Atomo Atomo is an Australian headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market. Atomo’s unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has successfully commercialised a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases including HIV, COVID-19, viral vs bacterial differentiation, as well as the early detection of pregnancy. See more at www.atomodiagnostics.com Atomo Diagnostics Limited ACN 142 925 684 Level 1, 3-5 George St Leichhardt NSW 2040